Lundbeck's Vyepti Recommended for Approval in EU for Migraine Prevention

Freitag, 12.11.2021 13:35 von PLX

• (PLX AI) – Lundbeck's Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults.
• • Subject to final approval by the European Commission, Vyepti (eptinezumab) will be the first intravenous (IV) treatment approved for migraine prevention in Europe
• • A final decision regarding the approval of Vyepti is expected from the European Commission in the coming months